Streptococcus pneumoniae: Nasopharyngeal and Oropharyngeal Carriage in Nursing Home Residents
- Conditions
- naso-/oropharyngeal pneumococcal carriagenaso-/oropharyngeal bacterial carriage
- Registration Number
- DRKS00004833
- Lead Sponsor
- niversitätsklinikum Jena
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 542
Inclusion Criteria
• Female and male nursing home residents in the age of 65 years and above living in one of the participating nursing homes
• Willingness to participate of nursing home resident or his/her legal guardian
• Written informed consent of participants or their legal guardians
Exclusion Criteria
• Lack of power of judgement (Mini Mental State Examination (MMSE) < 24 points) without legal guardian
• Refusal of participation by legal guardian
• actual Medication with immunosuppressant drugs with systemic effect
• Antibiotic use up to 10 days preceding swab
• Hospital stay up to 2 weeks preceding swab
• Nursing home residents with diagnosis of end stage malignoma
• Participation on other clinical trials during this observational study
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • Nasopharyngeal and oropharyngeal carriage of Streptococcus pneumoniae<br>• Serotype-specific nasopharyngeal and oropharyngeal carriage of Streptococcus pneumoniae<br>Exploratively: Nasopharyngeal and oropharyngeal carriage of Streptococcus pneumoniae adjusted for multimorbidity and functional status at day of swab taking<br>Evaluation of functional status by comprehensive geriatric assessment (i. e. geriatric screening (Lachs), mini mental state examination (Folstein)), evaluation of multimorbidity by Cumulative Illness Rating Scale, geriatric version.<br>
- Secondary Outcome Measures
Name Time Method • Other bacterial nasopharyngeal and oropharyngeal carriage <br>Exploratively: Other bacterial nasopharyngeal and oropharyngeal carriage than Streptococcus pneumoniae adjusted for multimorbidity and functional status at day of swab taking<br>Safety: <br>• Adverse events occuring within 24 hours following the swab<br>